Cempra Rises; Roth Capital Upgrades Ahead of Bone Data This Year
(Bloomberg) -- Cempra rises as much as 11% as Roth Capital Partners analyst Michael Higgins upgraded to buy from neutral, PT $8 from $2.50; Top-line results from the first of two skin infection (ABSSSI) studies with Taksta (fusidic acid) bode well for refractory bone and joint infections (BJI) data expected this year, he says.
- "Most impressed" with the 100% efficacy in the 99 patients with MRSA infections, which demonstrates a "strong efficacy profile" and is supportive for ongoing BJI trial
- The dosing in BJI trial is an extension of the dosing in this ABSSSI trial
- While the drug’s role in ABSSSI is compelling, its value in bone and joint infections is "far greater"
- Says Taksta’s primary commercial potential lies in treating prosthetic joint infections (PJIs) and BJIs
- FDA approval for Taksta in ABSSSI is "likely;" not clear if and when an NDA will be filed in BJI
- Notes that Taksta has been used in Europe for more than three decades
- NOTE: Reports 4Q earnings tomorrow pre-market, conf. call 8:45am
- NOTE: CEMP has 1 buy, 11 holds, 2 sells, avg PT $4.69: Bloomberg
To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.net To contact the editors responsible for this story: Arie Shapira at ashapira3@bloomberg.net Morwenna Coniam
Alert:
HALISTER1Source: BFW (Bloomberg First Word)
Tickers CEMP US (Cempra Inc)
People Michael Higgins (Roth Capital Partners LLC)
To de-activate this alert, click
hereTo modify this alert, click
hereUUID: 7947283